Volume 58, Issue 3 (7 2000)
Tehran Univ Med J 2000, 58(3): 53-56 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Akbari Asbagh F. Dexamethasone is an effective, safe and cost benefit medication for resistant anovulatory normal hydroepiandrosterone Sulfate patients. Tehran Univ Med J 2000; 58 (3) :53-56
URL: http://tumj.tums.ac.ir/article-1-1388-en.html
URL: http://tumj.tums.ac.ir/article-1-1388-en.html
Abstract: (11157 Views)
Clomiphene critrate is an effective and safe treatment for anovulation, but in some cases resistance occurs. To evaluate the efficacy of Dexamethasone in resistant anovulatory normal Dehydroepiandrosterone patients, we prospectively studied 57 infertile resistant anovulatory women. Each woman received 100 mg daily clomiphene critrate from cycle days 3-7 and 0.5 mg Dexamethasone from cycle days 3-12 at night. Serial ultrasonography was performed and hCG (5000-10000 IU) was administered when the follicles reached 17-18 mm in diameter. Ovulation in 80.7% and clinical pregnancy in 29.3% patients were achieved in 92 treatment cycles. The average dominant follicles>16.1 mm was 2.42. The endometrium thickness in 61.4% was greater than 8 mm. Nor adverse reaction of clomiphene critrate neither hyperstimulation were encountered. Ovulation and pregnancy rates were similar in both primary and secondary infertile groups. According to low cost, less side effects and effectiveness, we recommend combination of clomiphene critrate and Dexamethasone in patients with normal DHEAS resistant anovulation.
Keywords: Anovulation
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
